Laryngeal cancer Cancer
Conditions
Interventions
This study is the first enhanced laryngeal cancer disease cohort. We aim to deliver a cross-sectional study of 150 patients. Patient, tumour, quality-of-life and laryngeal functional data will be coll
Sponsors
Newcastle upon Tyne Hospitals NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Confirmed new diagnosis of laryngeal cancer (Group 2) 2. Suspected but unconfirmed laryngeal cancer (Group 1) 3. Aged 18 years old and over 4. Capacity to consent 5. Ability to understand written and spoken English
Exclusion criteria
Exclusion criteria: 1. Aged 17 years old and younger 2. No capacity to consent 3. Recurrence or second head and neck primary cancer 4. Not able to adequately understand written or spoken English
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Tumour status measured by clinical assessment at 6, 12 and 24 months 2. Disease-specific survival measured using disease status at 6, 12 and 24 months 3. Overall survival measured at 6, 12 and 24 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Laryngeal function measured using GRBAS (grade, roughness, breathiness, asthenia, strain) scale, maximum phonation time, Voice Handicap Index (VHI-10), MD Anderson Dysphagia Inventory (MDADI), Performance Status Scale for Head & Neck Cancer Patients (PSS-HN), Videofluoroscopic Swallow Study (VFSS) and Flexible Endoscopic Evaluation of Swallowing (FEES) at baseline, 6, 12 and 24 months 2. Quality of life measured using EORTC Core Quality of Life questionnaire (EORTC QLQ-C30) and the EORTC Head and Neck Cancer Module (EORTC HN35) at baseline, 6, 12 and 24 months 3. Swallow measured using MDADI, PSS-HN, VFSS and FEES at baseline, 6, 12 and 24 months 4. Voice outcome measured using GRBAS, maximum phonation time, VHI-10 at baseline, 6, 12 and 24 months | — |
Countries
England, United Kingdom
Contacts
Public ContactDavid Hamilton
Outcome results
None listed